Mdma molecule:

Image from PubChem

Mdma Clinical Trials

Phase 2, Multiple-Site, Open-Label, Randomized, 2-Group, Parallel Study to Assess the Efficacy and Safety of Ryanodex(R) (EGL-4101)as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

To see complete record on, please visit this link

Id: NCT03189433

Organisation Name: Eagle Pharmaceuticals, Inc.

Overal Status: Terminated

Start Date: August 12, 2017

Last Update: March 30, 2021

Lead Sponsor: Eagle Pharmaceuticals, Inc.

Brief Summary: Ryanodex is being investigated as a potential adjuvant treatment for people suffering from psychostimulant drug-induced toxicity (PDIT), a life-threatening medical condition that results mainly from the abuse of certain illicit drugs, most notably methamphetamine, and related forms (MDMC or "Molly"; MDMA or "Ecstasy"). Ryanodex is approved for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for prevention of malignant hyperthermia in patients at high risk and in this study, will be investigated for the treatment of PDIT. The hypothesis of this study is that administration of Ryanodex as adjuvant treatment to Standard of Care (SOC) will improve the clinical outcome compared with SOC alone, in subjects with psychostimulant drug induced toxicity. Current SOC is defined as body cooling and supportive measures.

  • Drug Toxicity Psychotropic Agents Psychostimulants

Total execution time in seconds: 0.30963611602783